Health & Biotech
Strong growth boosts Control Bionics’ US revenue in H1 FY25
Positive interim study results for Neurizon’s motor neurone disease drug
Crucible: Dr Boreham’s A-To-Z of 2024 biotech
Tryptamine’s psilocin infusion study reveals solid results in obese
Health Check: Hearts are pumping as Anteris shares debut on the Nasdaq
Control Bionics leaps into new US and Japanese markets with strategic deals
Scott Power: The lowdown on Sonic’s $700m German excursion
First sales in Singapore for Orthocell’s nerve-repair product Remplir
Biocurious: IPO candidate Nexsen Biotech tackles global infant killer with early diagnosis tool
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
ReNerve inks Middle East distribution deal for nerve repair product NervAlign
Wellnex ready for dual UK listing in new year after record November sales
LTR Pharma successfully completes $25m cap raise to accelerate novel ED treatment
Health Check: The robots are taking over biotech stock selection
Dr Boreham’s Crucible: ‘The sun is coming up’ for this skin-regeneration specialist
Paradigm raises $16m for phase III trial of knee osteoarthritis treatment
Health Check: Booming Sonic seals a $700 million German acquisition
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
